Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 7/20 | 0.44 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3535291 | 0.95 | AVPR2 (0.45) | AVPR2AVPR1ALMNA | |
| SCHEMBL3531924 | 0.94 | AVPR2 (0.43) | AVPR2AVPR1ATP53LMNA | |
| SCHEMBL3535842 | 0.94 | AVPR2 (0.43) | AVPR2AVPR1ALMNA | |
| SCHEMBL3533941 | 0.94 | AVPR2 (0.43) | AVPR2AVPR1ATP53LMNAMAPT | |
| SCHEMBL3535917 | 0.94 | AVPR2 (0.43) | AVPR2AVPR1ATP53LMNAMAPT | |
| SCHEMBL3533374 | 0.92 | AVPR2 (0.47) | AVPR2AVPR1ATP53LMNAALDH1A1 | |
| SCHEMBL3534477 | 0.92 | AVPR1A (0.42) | AVPR2AVPR1ATP53LMNAALDH1A1 | |
| SCHEMBL3532196 | 0.92 | LMNA (0.46) | AVPR2AVPR1ATP53LMNAMAPT | |
| SCHEMBL3533015 | 0.92 | AVPR2 (0.43) | AVPR2AVPR1ATP53MAPTTDP1 | |
| SCHEMBL3533195 | 0.92 | AVPR2 (0.43) | AVPR2AVPR1ATP53LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691848-B2 | Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2010-04-06 | — | — | US | claimed |
| US-20060199806-A1 | Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2006-09-07 | — | — | US | claimed |
| US-7691848-B2 | Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2010-04-06 | — | — | US | disclosed |
| US-20060199806-A1 | Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199806-A1 | Pyrrolobenzodiazepine arylcarboxamides and derivatives thereof as follicle-stimulating hormone receptor antagonists | FSHR, GNRHR, LHCGR | AVPR2 31/4885AVPR1A 63/4885TP53 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.